Welcome to our dedicated page for CVRx SEC filings (Ticker: CVRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CVRx, Inc. filings document a Nasdaq-listed medical device company commercializing Barostim neuromodulation therapy for cardiovascular disease. Its Form 8-K reports record financial results releases, preliminary operating updates, material agreements, equity offering arrangements, amendments to its loan and security agreement, and executive compensation actions tied to performance stock units.
Proxy filings describe annual meeting matters, director elections, auditor ratification, board structure and stockholder voting procedures. The company’s SEC record also identifies its common stock, emerging growth company status, governance disclosures and capital-structure matters associated with debt and at-the-market equity financing.
CVRx, Inc. reported preliminary first quarter 2026 results showing total revenue of $14.7–$14.8 million, up from $12.3 million a year earlier, which is about 20% growth. Gross margin is expected to improve to roughly 87% from 84%, while total operating expenses are projected at about $25 million versus $23.7 million.
As of March 31, 2026, CVRx had 257 U.S. active implanting centers and 56 U.S. sales territories, and held approximately $72.3 million in cash and cash equivalents. The company highlights improved reimbursement after Category I CPT codes took effect, with 30‑day Medicare Advantage prior authorization approval rates rising from 31% in 2024 to 44% in 2025 and 50% for the first two months of 2026.
CVRx also activated the first site in its BENEFIT‑HF randomized trial on March 31, 2026, with enrollment expected to begin in the second quarter. If successful, this study could expand the indicated patient population for Barostim by about three times.
CVRx, Inc. reported that Chief Medical Officer Philip B. Adamson received new equity awards and completed a small share sale tied to tax withholding. On February 27, 2026, he was granted stock options for 62,000 shares of common stock at an exercise price of $8.16 per share, expiring on February 26, 2036, along with 41,000 restricted stock units. The restricted stock units vest 25% on each annual anniversary of the grant date, and the options vest 25% on February 27, 2027 with the remainder vesting monthly thereafter. On March 2, 2026, he sold 1,262 shares of common stock at a weighted average price of about $7.90 per share in multiple trades between $7.90 and $8.00, a sale that was mandated by the award agreement to satisfy tax withholding obligations through a sell-to-cover transaction. Following these transactions, he directly held 61,578 common shares.
Morrison Gregory reported acquisition or exercise transactions in this Form 4 filing.
CVRx, Inc. reported that Chief Human Resources Officer Gregory Morrison received equity awards on March 2, 2026. He was granted 154,500 stock options and 34,000 shares of common stock at no cost. The common stock represents restricted stock units vesting 25% annually, while the options vest 25% on March 2, 2027 and monthly thereafter.
CVRx, Inc. filed an initial statement of beneficial ownership for executive Gregory Morrison, who serves as Chief Human Resources Officer. This Form 3 establishes his status as an insider of the company and provides the baseline disclosure of his equity holdings for future reporting under securities rules.
CVRx, Inc. president and CEO Kevin Hykes reported both an equity award and a small tax-related sale. He received a grant of 238,000 stock options and 159,000 restricted shares, which vest over several years. To cover tax withholding from these awards, he sold 7,763 common shares at a weighted average price of $7.9027 per share in mandated sell-to-cover transactions. After these trades, he directly owned 284,237 common shares.
CVRx, Inc. Chief Marketing & Strategy Officer Paul Verrastro reported a mix of equity grants and a small sale. On February 27, 2026, he acquired 45,000 shares of common stock as restricted stock units and a 67,000-share stock option grant, both at no cost.
The restricted stock units vest 25% on each annual anniversary of the grant date, while the option vests 25% on February 27, 2027 and then monthly in equal installments. On March 2, 2026, he sold 1,284 shares of common stock at a weighted average price of $7.9021 per share, in transactions ranging from $7.90 to $7.98, to satisfy tax withholding obligations through a mandated sell-to-cover transaction. Following the sale, he directly held 60,551 shares of common stock and 67,000 stock options.
CVRx, Inc. chief financial officer Jared Oasheim reported a mix of equity grants and a small mandated share sale. He received a grant of 91,000 stock options at an exercise price of $0.0000 per share, vesting 25% on February 27, 2027 and then monthly thereafter. He was also granted 61,000 shares of common stock in the form of restricted stock units that vest 25% on each annual anniversary of the grant date. To cover tax withholding obligations from these awards, he sold 1,744 shares of common stock in an open-market sell-to-cover transaction on March 2, 2026 at a weighted-average price of $7.9022 per share, with individual sale prices ranging from $7.90 to $7.9831. After these transactions, he directly held 96,703 shares of common stock.
CVRx, Inc. Chief Revenue Officer John Robert Allen reported a mix of stock sales and awards. He sold 3,964 shares of common stock in an open-market transaction at a weighted average price of $7.9025 per share to cover tax withholding obligations from equity awards. He also received a grant of 35,000 restricted stock units and 52,000 stock options, both vesting over several years starting on February 27, 2027, increasing his long-term equity exposure to the company.
CVRx, Inc. chief operating officer Brent Binkowski reported equity awards on February 27, 2026. He received 23,000 stock options with an exercise price of $0.00 per share and a separate grant of 15,000 shares of common stock, both classified as awards rather than open-market purchases.
The 15,000-share common stock grant consists of restricted stock units that vest in four equal annual installments of 25% on each anniversary of the grant date. The 23,000-stock-option award vests as to 25% of the shares on February 27, 2027, with the remaining shares vesting in equal monthly installments over the following 36 months. After these transactions, Binkowski directly owned 31,600 shares of common stock, according to the filing.
CVRx, Inc. approved a new performance stock unit (PSU) program for its executive officers tied to a cumulative revenue goal over the fiscal 2026–2027 period. This incremental award is in addition to their regular annual equity grants.
For named executive officers, the grant date value of these PSUs equals three-fourths of their 2026 annual long-term incentive value. Payouts range from 50% of target at threshold performance to 200% at maximum. Any earned PSUs vest 50% after the revenue goal is certified and 50% on December 31, 2028, generally requiring continued employment and including provisions for accelerated or continued vesting upon death, disability, certain terminations, or qualifying change in control events.